Skip to content

Triggering of Follicular Maturation

Triggering of Follicular Maturation Using Human Chorionic Gonadotrophin With Gonadotrophin Releasing Hormone Agonist Versus Human Chorionic Gonadotrophin Alone in Antagonist Protocol in Assisted Reproductive Technology : a Randomized Controlled Trial

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02916173
Enrollment
160
Registered
2016-09-27
Start date
2016-11-30
Completion date
2019-02-28
Last updated
2019-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Increase Pregnancy Rate

Brief summary

The follicular phase of the menstrual cycle involves the hourly release of gonadotropin-releasing hormone, which binds to receptors on the gonadotropes. This results in the secretion of follicle stimulating hormone and luteinizing hormone in hourly pulses that regulate follicular growth. At midcycle, rapidly rising estradiol from the dominant follicle and a small rise in progesterone lead to a gonadotrophic surge. An increase in the amplitude of Luteinizing hormone and Follicle stimulating hormone pulses initiates oocyte maturity and triggers ovulation approximately

Interventions

DRUGRecombinant Human Chorionic Gonadotrophin

250 unit intramuscular

DRUGhuman chorionic gonadotrophin + gonadotrophin releasing hormone agonist

250 unit intramuscular + 1 mg subcutaneous

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

1. Infertile couples wishing to do intracytoplasmic injection trial . 2. first intracytoplasmic injection trial 3. Body mass index:18-30. 5-Antral follicular count: more than 5 follicles in one ovary 6-normal, mild or moderate male factor infertility. 7- Antimullerian hormone \>1 ng/ml

Exclusion criteria

1. Azoospermic male. 2. Body mass index more than 29. 3. Patients with endometriosis . 4. Antimullerian hormone \< 1 ng/ml

Design outcomes

Primary

MeasureTime frame
Number of M II oocytes in both groups24 hours

Secondary

MeasureTime frame
Fertilization rate in each group3 days
Clinical pregnancy rate in each group15 days

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026